Aryl benzyl ether compound having affinity with monoamine oxidase B and application thereof
By developing high affinity and selectivity arylbenzyl ether compounds, the irreversible binding of existing MAO-B probes and blood-brain barrier penetration in brain imaging are solved, and the MAO-B is achieved Highly efficient imaging supports the early diagnosis and treatment of neurodegenerative diseases.
Patent Information
- Application Number
- CN202410765512.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-14
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-06-14
AI Technical Summary
The existing MAO-B probes have irreversible binding properties and blood-brain barrier penetrating radiometabolites interference in intracerebral imaging, and the 18F labeled probe has a short half-life, which limits its application range and is difficult to achieve high affinity and selection. and excellent pharmacokinetics affect the early diagnosis and treatment of neurodegenerative diseases.
Develop a high affinity and selectivity arylbenzyl ether compound labeled by radioisotope 18F for nuclear medicine imaging, especially for imaging activated astrocytes in the brain, as MAO-B targeted molecular probes and potential surrogate markers for diagnosis and treatment of neurodegenerative diseases, including Alzheimer's disease.
This compound can effectively cross the blood-brain barrier, has high affinity and selectivity, and is used for imaging of MAO-B, providing scientific research and clinical guidance value for the early diagnosis and treatment of neurodegenerative diseases, and its derivatives are available Evaluation of drug dosage and efficacy.
Smart Images

Figure CN119060024A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical fields of pharmaceutical chemistry and clinical nuclear medicine, and in particular to an aryl benzyl ether compound having high affinity with monoamine oxidase B and application thereof. Background Art
[0002] Monoamine oxidase (MAOs) is a flavin enzyme highly expressed in the outer membrane of mitochondria of neurons, astrocytes and other cells. It can be divided into two subtypes, MAO-A and MAO-B, based on substrate specificity and sensitivity to inhibitors. MAO-B is the main subtype present in the central nervous system, distributed in the basal forebrain, brainstem, basal ganglia and thalamus, and is responsible for 70% of the MAO activity in the whole brain. In the normal aging process, the activity and expression of MAO-B gradually increase with age.
[0003] Astrocytes are an important type of glial cell that plays an important role in the regulation and maintenance of the blood-brain barrier, the formation and ablation of synapses, and the circulation of neurotransmitters. Infection, injury, and disease of the central nervous system can cause the activation of astrocytes, a process called astrocyte reactivity. Reactive astrocytes undergo structural and functional changes, including cell hypertrophy, enhanced proliferation, increased glial fibrillary acid protein and vimentin, and overexpression of MAO-B on their mitochondrial outer membrane. Literature reports that the expression level of MAO-B in the brain of patients with neurodegenerative diseases such as Alzheimer's Disease (AD), Parkinson's Disease (PD), Progressive supranuclear palsy (PSP), and multiple-system atrophy (MSA) is increased, which can reflect the neuroinflammation caused by the activation of glial cells in the brain of the above diseases. The unique biological and pathological characteristics of MAO-B indicate that it can be used as a potential target for imaging reactive glial cells during neuroinflammation.
[0004] Currently, some molecular probes targeting MAO-B have been reported. 11 C]-L-deprenyl-D2([ 11 C]DED) is one of the most commonly used probes for imaging MAO-B in the brain, but its irreversible binding properties and the presence of blood-brain barrier (BBB) penetrable radioactive metabolites interfere with the precise quantification of imaging results. 11 C]SL25.1188 can bind reversibly to MAO-B, but 11 The short half-life of C (20.4 minutes) limits its use to PET centers with cyclotrons. 18Currently, the only F-labeled probes are 18 F]SMBT-1 has been reported to be useful for imaging activated astrocytes in the brains of AD patients, so the development of a new 18 The F-labeled MAO-B probe with high affinity, high selectivity and excellent pharmacokinetic properties has high scientific research value and clinical guidance significance for the early diagnosis and targeted treatment of neurodegenerative diseases and neuroinflammatory diseases. Summary of the invention
[0005] The present invention provides an aryl benzyl ether compound with high affinity to monoamine oxidase B (MAO-B) and its application. The compound has high affinity and selectivity for MAO-B and can be used as a MAO-B inhibitor; at the same time, after being labeled with a suitable radioisotope, it can be used for nuclear medicine imaging, especially for imaging activated astrocytes in the brain.
[0006] In the first aspect, the aryl benzyl ether compound provided by the present invention has the following general formula (I):
[0007]
[0008] in:
[0009] X1 represents N or CH; X2, X3 each independently represent O or CH2;
[0010] R1, R2, and R3 each independently represent H, 123 / 124 / 125 / 127 I. 18 / 19 F or O(CH2) n 18 / 19 F, n represents 1-6;
[0011] Ar represents
[0012] The compound of general formula (I) with aryl benzyl ether structure as the main body provided by the present invention has high affinity and selectivity for monoamine oxidase B. 18 After F labeling, the drug can be used as a molecular probe targeting MAO-B and a potential alternative marker for reactive astrocytes for nuclear medicine imaging. It is expected to be applicable to the diagnosis, drug dosing and efficacy evaluation of patients with neurodegenerative diseases characterized by upregulated MAO-B expression, including Alzheimer's disease, progressive supranuclear palsy, primary age-related tauopathy, Pick's disease, corticobasal degeneration, glial cell spherical inclusion tauopathy, amyotrophic lateral sclerosis and Parkinson's disease.
[0013] Preferably, the aryl benzyl ether compound is selected from the following compounds:
[0014]
[0015]
[0016] Among them, F in compound 1-19 is 18 F or 19 F.
[0017] The above preferred compounds have higher activity, higher affinity and selectivity for MAO-B.
[0018] In the second aspect: the present invention provides derivatives of the aryl benzyl ether compounds which are pharmaceutically acceptable salts, esters or amide compounds or prodrugs of the aryl benzyl ether compounds.
[0019] Preferably, the pharmaceutically acceptable salts of the aryl benzyl ether compounds include hydrochlorides, phosphates and sulfonates of the aryl benzyl ether compounds.
[0020] In a third aspect, the present invention provides a monoamine oxidase B inhibitor, the active ingredient of which is the aryl benzyl ether compound as described in the first aspect, or a derivative of the aryl benzyl ether compound as described in the second aspect.
[0021] Fourth aspect: The present invention provides a diagnostic or detection reagent for central nervous system diseases characterized by upregulated expression of monoamine oxidase B, the active ingredient of which is the aryl benzyl ether compound as described in the first aspect above, or a derivative of the aryl benzyl ether compound as described in the second aspect above.
[0022] Preferably, the disease includes Alzheimer's disease, Parkinson's disease, frontotemporal lobar degeneration, chronic traumatic encephalopathy, progressive supranuclear palsy, primary age-related tauopathy, Pick's disease, corticobasal degeneration, glial cell globular inclusion tauopathy, amyotrophic lateral sclerosis and Lewy body dementia.
[0023] In a fifth aspect, the present invention provides use of the aryl benzyl ether compounds described in the first aspect, or derivatives of the aryl benzyl ether compounds described in the second aspect, in the preparation of nuclear medicine imaging agents.
[0024] Specifically, the nuclear medicine imaging agent is a PET imaging agent. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] In order to more clearly illustrate the technical solutions in the embodiments of the present application, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are some embodiments of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0026] Figure 1 Schematic diagram of the synthesis process of the compounds of Example 1-30 of the invention, wherein the reaction reagents and conditions involved are: (a) potassium carbonate, acetonitrile or N,N-dimethylformamide, 90-120°C, 3 hours; (b) 1-bromo-2-fluoroethane, acetone, potassium carbonate, 80°C, 3 hours; (c) sodium borohydride, methanol, 0°C, 30 minutes; (d) phosphorus tribromide, dichloromethane, 0°C to room temperature, 2 hours; (e) m-chloroperbenzoic acid, dichloromethane, room temperature, 3 hours; (f) p-toluenesulfonic anhydride, trimethylamine (1M tetrahydrofuran solution), dichloromethane, room temperature, 10 hours; (g) [ 18 F]F - , Kryptofix 2.2.2, potassium carbonate, anhydrous acetonitrile, 65°C, 5 minutes; (h) p-toluenesulfonic anhydride, chloroform, room temperature, 3 hours; adamantyl substituted auxiliary acid, sodium carbonate (10% aqueous solution), ethanol, room temperature, 30 minutes; (i) [ 18 F]F - , Kryptofix 2.2.2, potassium carbonate, anhydrous N,N-dimethylformamide, 120°C, 10 minutes.
[0027] Figure 2 is the labeled compound in Example 35 of the present invention [ 18 F]2 or [ 18 F]9 in rats autoradiography inhibition experiment and immunofluorescence staining results.
[0028] Figure 3 is the labeled compound in Example 37 of the present invention [ 18 F]2 PET imaging results in SD rats, Figure 3 A is [ 18 F]2 time activity curve in the brain of SD rats in the control group and inhibition group after injection; Figure 3 B is the micro-PET / CT imaging results of the cross-section, coronal, and sagittal planes of SD rats at different time periods after tracer injection and the whole-body MIP map at 60 minutes.
[0029] Figure 4 is the labeled compound in Example 37 of the present invention [ 18 F]9 PET imaging results in SD rats, Figure 4 A is [ 18 F] Time activity curve of 9 in the brain of SD rats in the control group and inhibition group after injection; Figure 4 B is the micro-PET / CT imaging results of the cross-section, coronal, and sagittal planes of SD rats at different time periods after tracer injection and the whole-body MIP map at 60 minutes.
[0030] Figure 5 is the labeled compound in Example 38 of the present invention [ 18 F]2PET imaging results in APP / PS1 model mice and C57BL / 6 control mice. DETAILED DESCRIPTION
[0031] In order to facilitate the understanding of the present invention, the implementation process of the present invention is further described below in conjunction with specific implementation examples. These descriptions are only for further illustrating the features and advantages of the present invention, rather than limiting the claims of the invention.
[0032] Example 1: Synthesis of standard compound 1
[0033]
[0034] 2-Fluoro-5-hydroxypyridine (13.8 mg, 0.12 mmol) and 7-bromomethylcoumarin (29.2 mg, 0.12 mmol) were dissolved in 10 mL DMF, potassium carbonate (84.3 mg, 0.60 mmol) was added, and refluxed at 110°C for 2 hours. After the reaction was completed, DMF was removed under reduced pressure, 20 mL of dichloromethane was added, ultrasonication was performed, and dichloromethane was removed under reduced pressure. Recrystallization gave 18.6 mg of a white solid with a yield of 57.1%. 1 H NMR (600MHz, DMSO-d6) δ8.08(d,J=9.5Hz,1H),8.00(s,1H),7.75(d,J=7.9Hz,1H),7.70(t,J=6.1Hz,1H ),7.50(s,1H),7.44(d,J=7.8Hz,1H),7.15(dd,J=8.8,2.8Hz,1H),6.51(d,J=9.5Hz,1H),5.31(s,2H).
[0035] Example 2: Synthesis of standard compound 2
[0036]
[0037] According to the preparation method of compound 1, compound 2 was prepared using 5-bromomethyl-2-fluoropyridine and 7-hydroxycoumarin as raw materials. The product was a white solid (220.5 mg) with a yield of 81.3%. 1H NMR (400MHz, CDCl3) δ8.31(s,1H),7.90(td,J=8.0,2.6Hz,1H),7.65(d,J=9.5Hz,1H),7.41(d,J=8 .5Hz,1H),7.00(dd,J=8.4,3.1Hz,1H),6.90(d,J=9.3Hz,2H),6.29(d,J=9.5Hz,1H),5.12(s,2H).
[0038] Example 3: Synthesis of standard compound 3
[0039]
[0040] According to the preparation method of compound 1, compound 3 was prepared using 5-bromomethyl-2-fluoropyridine and 2,4-dihydroxyacetophenone as raw materials. The product was a white solid (212.9 mg) with a yield of 81.5%. 1 H NMR(400MHz, CDCl3) δ8.29(d,J=2.1Hz,1H),7.88(td,J=8.3,2.5Hz,1H),7.70–7.6 3(m,1H),6.99(dd,J=8.4,2.9Hz,1H),6.53–6.48(m,2H),5.08(s,2H),2.57(s,3H).
[0041] Example 4: Synthesis of Standard Compound 4
[0042]
[0043] According to the preparation method of compound 1, compound 4 was prepared using 5-bromomethyl-2-fluoropyridine and 4-hydroxyacetophenone as raw materials. The product was a white solid (184.7 mg) with a yield of 75.3%. 1 H NMR (400MHz, CDCl3) δ8.30(s,1H),7.96(d,J=8.8Hz,2H),7.89(td,J=8.1,2.4Hz,1H),7.00(dd,J=8.5,4.1Hz,3H),5.12(s,2H),2.57(s,3H).
[0044] Example 5: Synthesis of standard compound 5
[0045]
[0046] According to the preparation method of compound 1, compound 5 was prepared using 5-bromomethyl-2-fluoropyridine and 3-hydroxy-4H-1-benzopyran-4-one as raw materials. The product was a white solid (196.1 mg) with a yield of 72.3%. 1H NMR (400MHz, CDCl3) δ8.28(dd,J=8.0,1.6Hz,1H),8.25(d,J=2.0Hz,1H),7.98(td,J=8.0,2.5Hz,1H),7.82(s,1H),7.6 7(ddd,J=8.6,7.1,1.6Hz,1H),7.45(d,J=8.5Hz,1H),7.41(t,J=7.6Hz,1H),6.96(dd,J=8.4,2.9Hz,1H),5.17(s,2H).
[0047] Example 6: Synthesis of Standard Compound 6
[0048]
[0049] According to the preparation method of compound 1, compound 6 was prepared using 5-bromomethyl-2-fluoropyridine and 6-hydroxy-2H-benzofuran-3-one as raw materials. The product was a white solid (187.4 mg) with a yield of 72.4%. 1 H NMR(400MHz, CDCl3)8.31(s,1H),7.89(td,J=8.0,2.5Hz,1H),7.61(d,J=8.6Hz,1H),7.01(dd,J =8.4,2.9Hz,1H),6.72(dd,J=8.6,2.1Hz,1H),6.63(d,J=2.1Hz,1H),5.12(s,2H),4.64(s,2H).
[0050] Example 7: Synthesis of standard compound 7
[0051]
[0052] According to the preparation method of compound 1, compound 7 was prepared using 2-fluorobenzyl bromide and 7-hydroxycoumarin as raw materials. The product was a white solid (75.9 mg) with a yield of 81.9%. 1 H NMR (600MHz, DMSO-d6) δ8.00(d,J=9.5Hz,1H),7.65(d,J=8.6Hz,1H),7.59(td,J=7.6,1.6Hz,1H),7.49–7.39(m ,1H),7.30–7.23(m,2H),7.13(d,J=2.4Hz,1H),7.03(dd,J=8.6,2.4Hz,1H),6.31(d,J=9.5Hz,1H),5.25(s,2H).
[0053] Example 8: Synthesis of Standard Compound 8
[0054]
[0055] According to the preparation method of compound 1, compound 8 was prepared using 3-fluorobenzyl bromide and 7-hydroxycoumarin as raw materials. The product was a white solid (65.4 mg) with a yield of 89.3%. 1 H NMR (400MHz, CDCl3) δ7.64(d,J=9.5Hz,1H),7.42–7.34(m,2H),7.20(d,J=7.7Hz,1H),7.15(d,J=9.5Hz,1H),7.0 4(td,J=8.4,2.3Hz,1H),6.92(dd,J=8.6,2.4Hz,1H),6.87(d,J=2.4Hz,1H),6.27(d,J=9.5Hz,1H),5.13(s,2H).
[0056] Example 9: Synthesis of Standard Compound 9
[0057]
[0058] According to the preparation method of compound 1, compound 9 was prepared using 4-fluorobenzyl bromide and 7-hydroxycoumarin as raw materials. The product was a white solid (224.9 mg) with a yield of 83.2%. 1 H NMR (400MHz, CDCl3) δ7.64(d,J=9.5Hz,1H),7.44–7.37(m,3H),7.10(t,J=8.6Hz,2H),6.93–6.87(m,2H),6.26(d,J=9.5Hz,1H),5.09(s,2H).
[0059] Example 10: Synthesis of standard compound 10
[0060]
[0061] According to the preparation method of compound 1, compound 10 was prepared using 2-fluorophenol and 7-bromomethylcoumarin as raw materials. The product was a white solid (35.8 mg) with a yield of 83.5%. 1 H NMR (600MHz, DMSO-d6) δ8.07(d,J=9.5Hz,1H),7.75(d,J=7.9Hz,1H),7.47(s,1H),7.44(d,J=7.9Hz, 1H),7.29–7.17(m,2H),7.12(t,J=7.8Hz,1H),7.02–6.89(m,1H),6.50(d,J=9.5Hz,1H),5.31(s,2H).
[0062] Example 11: Synthesis of Standard Compound 11
[0063]
[0064] According to the preparation method of compound 1, compound 11 was prepared using 3-fluorophenol and 7-bromomethylcoumarin as raw materials. The product was a white solid (94.3 mg) with a yield of 82.5%. 1 H NMR (600MHz, DMSO-d6) δ8.07(d,J=9.5Hz,1H),7.74(d,J=7.9Hz,1H),7.47(s,29H),7.42(dd,J=7.9,1.3Hz,1H),7.36–7.30(m, 1H), 6.93 (dt, J=11.3, 2.4Hz, 1H), 6.89 (dd, J=8.2, 2.1Hz, 1H), 6.79 (td, J=8.3, 2.2Hz, 1H), 6.50 (d, J=9.5Hz, 1H), 5.25 (s, 2H).
[0065] Example 12: Synthesis of standard compound 12
[0066]
[0067] According to the preparation method of compound 1, compound 12 was prepared using 4-fluorophenol and 7-bromomethylcoumarin as raw materials. The product was a white solid (95.7 mg) with a yield of 88.2%. 1 H NMR (600MHz, DMSO-d6) δ8.07(d,J=9.5Hz,1H),7.74(d,J=7.9Hz,1H),7.46(s,1H),7.42(d, J=7.9Hz,1H),7.14(t,J=8.8Hz,2H),7.10–6.99(m,2H),6.49(d,J=9.5Hz,1H),5.21(s,2H).
[0068] Example 13: Synthesis of standard compound 13
[0069]
[0070] According to the preparation method of compound 1, 2-fluorobenzyl bromide and 6-hydroxycoumarin were used as raw materials to prepare the standard compound 13. The product was a white solid (65.3 mg) with a yield of 79.8%. 1 H NMR (600MHz, DMSO-d6) δ8.01(d,J=9.6Hz,1H),7.58(t,J=7.4Hz,1H),7.43(dd,J=15.2,7 .1Hz,2H),7.36(d,J=9.0Hz,1H),7.33–7.23(m,3H),6.50(d,J=9.5Hz,1H),5.19(s,2H).
[0071] Example 14: Synthesis of Standard Compound 14
[0072]
[0073] According to the preparation method of compound 1, 3-fluorobenzyl bromide and 6-hydroxycoumarin were used as raw materials to prepare standard compound 14. The product was a white solid (78.2 mg) with a yield of 83.9%. 1 H NMR (600MHz, DMSO-d6) δ8.01(d,J=9.6Hz,1H),7.52–7.42(m,1H),7.41–7.28(m,5H),7.23–7.12(m,1H),6.50(d,J=9.5Hz,1H),5.18(s,2H).
[0074] Example 15: Synthesis of standard compound 15
[0075]
[0076] According to the preparation method of compound 1, compound 15 was prepared using 4-fluorobenzyl bromide and 6-hydroxycoumarin as raw materials. The product was a white solid (94.9 mg) with a yield of 91.6%. 1 H NMR(600MHz,DMSO-d6)δ8.01(d,J=9.6Hz,1H),7.52(s,2H),7.43–7.34(m,2H),7. 28(dd,J=9.0,3.0Hz,1H),7.27–7.20(m,2H),6.50(d,J=9.5Hz,1H),5.13(s,2H).
[0077] Example 16: Synthesis of Standard Compound 16
[0078]
[0079] According to the preparation method of compound 1, compound 16 was prepared using 2-fluorophenol and 6-bromomethylcoumarin as raw materials. The product was a white solid (75.2 mg) with a yield of 87.9%. 1 H NMR (600MHz, DMSO-d6) δ8.15–8.07(m,1H),7.82(d,J=1.9Hz,1H),7.70(dd,J=8.5,2.0Hz,1H),7.44(d,J=8.5Hz,1H),7.27(td,J= 8.6, 1.3Hz, 1H), 7.23 (ddd, J=11.8, 8.1, 1.4Hz, 1H), 7.13 (t, J=7.9Hz, 1H), 7.00–6.89 (m, 1H), 6.52 (d, J=9.5Hz, 1H), 5.23 (s, 2H).
[0080] Example 17: Synthesis of Standard Compound 17
[0081]
[0082] According to the preparation method of compound 1, compound 17 was prepared using 3-fluorophenol and 6-bromomethylcoumarin as raw materials. The product was a white solid (78.4 mg) with a yield of 81.2%. 1 H NMR (600MHz, DMSO-d6) δ8.10(d,J=9.6Hz,1H),7.82(d,J=1.9Hz,1H),7.69(dd,J=8.5,2.1Hz,1H),7.44(d,J=8.5Hz,1H),7.39–7.28 (m,1H),6.93(dt,J=11.3,2.4Hz,1H),6.88(dd,J=8.2,2.1Hz,1H),6.79(td,J=8.5,2.4Hz,1H),6.52(d,J=9.5Hz,1H),5.18(s,2H).
[0083] Example 18: Synthesis of Standard Compound 18
[0084]
[0085] According to the preparation method of compound 1, compound 18 was prepared using 4-fluorophenol and 6-bromomethylcoumarin as raw materials. The product was 87.3 mg of a white solid with a yield of 93.0%. 1 H NMR (600MHz, DMSO-d6) δ8.09(d,J=9.6Hz,1H),7.80(d,J=1.8Hz,1H),7.68(dd,J=8.5,2.0Hz,1H),7.43( d,J=8.5Hz,1H),7.13(t,J=8.8Hz,2H),7.04(dd,J=9.1,4.4Hz,2H),6.52(d,J=9.5Hz,1H),5.14(s,2H).
[0086] Example 19: Synthesis of Intermediate Compound 19
[0087]
[0088] 4-Hydroxybenzaldehyde (800 mg, 6.55 mmol) and 1-bromo-2-fluoroethane (4175.9 mg, 32.75 mmol) were dissolved in 30 mL of acetone, potassium carbonate (1810.6 mg, 13.1 mmol) was added, and refluxed at 80°C for 3 hours. After the reaction was completed, the mixture was filtered and the acetone was removed under reduced pressure. The product was 1057.5 mg of a yellow oily liquid with a yield of 96.0%.1 H NMR(400MHz, CDCl3)δ9.88(s,1H),7.88–7.78(m,2H),7.06–6.99(m,2H),4 .85–4.82(m,1H),4.73–4.70(m,1H),4.34–4.31(m,1H),4.27–4.24(m,1H).
[0089] Example 20: Synthesis of Intermediate Compound 20
[0090]
[0091] 5-Bromomethyl-2-fluoropyridine 9 (350 mg, 2.08 mmol) was dissolved in 10 mL of methanol, sodium borohydride (157.5 mg, 4.16 mmol) was slowly added under ice bath, reacted for 30 minutes, and then quenched with water. Methanol was removed by distillation under reduced pressure, pH was adjusted to 7 with 1 M hydrochloric acid, and extracted with dichloromethane (3×10 mL), the organic phases were combined and dried over anhydrous MgSO4, filtered and evaporated under reduced pressure to remove the solvent to obtain 319.6 mg of colorless oily liquid, with a yield of 90.3%. 1 H NMR (600MHz, CDCl3) δ7.26 (dd, J = 8.7, 2.0Hz, 2H), 6.95–6.81 (m, 2H), 4.82–4.64 (m, 2H), 4.58 (s, 2H), 4.28–4.09 (m, 2H), 2.02 (s, 1H).
[0092] Example 21: Synthesis of Intermediate Compound 21
[0093]
[0094] The intermediate 20 (302.4 mg, 2.38 mmol) was dissolved in 10 mL of dichloromethane, and phosphorus tribromide (644.7 mg, 226 μL, 2.38 mmol) was slowly added dropwise at 0°C, and the mixture was returned to room temperature and the reaction was continued for 2 hours. After the reaction was completed, a saturated sodium bicarbonate solution was added, and the organic phase was dried over anhydrous MgSO4 after separation, and the solvent was removed by evaporation under reduced pressure to obtain 510.4 mg of a yellow oil with a yield of about 92.0%. Considering that the product may be easily deteriorated, it was directly carried out to the next step without further purification.
[0095] Example 22: Synthesis of Standard Compound 22
[0096]
[0097] According to the preparation method of compound 1, compound 22 was prepared using intermediate 21 and 7-hydroxycoumarin as raw materials. The product was a white solid (239.5 mg) with a yield of 76.2%.1 H NMR (400MHz, CDCl3) δ7.63(d,J=9.5Hz,1H),7.38(s,1H),7.36(s,1H),6.96(d,J=8.6Hz,2H),6.92–6.87(m,2H),6.26(d ,J=9.5Hz,1H),5.06(s,2H),4.83(t,J=4.0Hz,1H),4.71(t,J=4.0Hz,1H),4.27(t,J=4.0Hz,1H),4.20(t,J=4.0Hz,1H).
[0098] Example 23: Synthesis of Intermediate Compound 23
[0099]
[0100] According to the preparation method of compound 1, intermediate 23 was prepared using 3-bromomethylpyridine hydrobromide and 4-hydroxyacetophenone as raw materials. The product was a white solid (130 mg) with a yield of 57.2%. 1 H NMR (400MHz, CDCl3) δ8.70(s,1H),8.61(d,J=4.7Hz,1H),7.95(d,J=8.7Hz,2H),7.79(d,J =7.8Hz,1H),7.35(dd,J=8.0,4.8Hz,1H),7.01(d,J=9.0Hz,2H),5.15(s,2H),2.56(s,3H).
[0101] Example 24: Synthesis of Intermediate Compound 24
[0102]
[0103] Intermediate 23 (130.0 mg, 0.6 mmol) was dissolved in 15 mL of dichloromethane, and m-chloroperbenzoic acid (m-CPBA, 118.5 mg, 0.7 mmol) was added to the solution and reacted at room temperature for 3 hours. After the reaction was completed, dichloromethane was removed under reduced pressure, and 127.1 mg of a white solid was obtained by silica gel column separation with a yield of 91.7%. 1 H NMR (400MHz, CDCl3) δ8.37(s,1H),8.20(d,J=5.2Hz,1H),7.96(d,J=9.0Hz,2H),7.34(d,J=5.1Hz,2H),6.99(d,J=9.0Hz,2H),5.11(s,2H),2.57(s,3H).
[0104] Example 25: Synthesis of Precursor Compound 25
[0105]
[0106] The intermediate compound 24 (200 mg, 0.82 mmol) was dissolved in 20 mL of dichloromethane, and p-toluenesulfonic anhydride (535.27 mg, 1.64 mmol) was added. After stirring for 30 minutes, a tetrahydrofuran solution of trimethylamine (1M, 16.4 mL, 16.4 mmol) was slowly added. After stirring for 30 minutes, p-toluenesulfonic anhydride (267.64 mg, 0.82 mmol) was added. After stirring for 30 minutes, p-toluenesulfonic anhydride (267.64 mg, 0.82 mmol) was added twice. After reacting at room temperature for 10 hours, the organic phase was washed with saturated brine, and the organic phase was concentrated under reduced pressure. The obtained solid was dissolved in dichloromethane and added dropwise to rapidly stirred ether. A precipitate was precipitated, and the precipitate was transferred to a centrifuge tube for centrifugation, and the supernatant was discarded. Ether was added three times to wash the solid, and the supernatant was discarded after centrifugation. A white solid was obtained after vacuum drying. Further purification was carried out by preparative HPLC with a C18 reverse phase column and an acetonitrile-water solution (containing 0.1% TFA) as the mobile phase at a flow rate of 4 mL / min. The product retention time was 22.3 minutes. A white solid was obtained after freeze drying with an overall yield of 28.8%. 1 HNMR(400MHz,DMSO-d6)δ8.78(d,J=2.0Hz,1H),8.32(dd,J=8.6,2.2Hz,1H),8.12(d,J=8.7H z,1H),7.96(d,J=8.9Hz,2H),7.16(d,J=8.9Hz,2H),5.38(s,2H),3.59(s,9H),2.53(s,3H).
[0107] Example 26: Synthesis of Intermediate Compound 26
[0108]
[0109] According to the preparation method of compound 1, intermediate 26 was prepared using 3-bromomethylpyridine hydrobromide and 7-hydroxycoumarin as raw materials. The product was a white solid (381.0 mg) with a yield of 75.5%. 1 H NMR (400MHz, CDCl3) δ8.69(d,J=37.5Hz,2H),7.85(d,J=7.9Hz,1H),7.65(d,J=9.5H z,1H),7.41(d,J=8.5Hz,2H),6.95–6.88(m,2H),6.29(d,J=9.5Hz,1H),5.17(s,2H).
[0110] Example 27: Synthesis of Intermediate Compound 27
[0111]
[0112] Intermediate 26 (381.0 mg, 1.5 mmol) was dissolved in 15 mL of dichloromethane, and m-chloroperbenzoic acid (m-CPBA) (310.0 mg, 1.8 mmol) was added to the solution, and the mixture was reacted at room temperature for 3 hours. After the reaction was completed, dichloromethane was removed under reduced pressure, and 349.0 mg of a white solid was obtained by silica chromatography separation with a yield of 86.4%. 1 H NMR (400MHz, CDCl3) δ8.94(s,1H),7.60(s,1H),7.49(d,J=6.5Hz,2H),7.46–7.33(m,4H),6.51(d,J=7.8Hz,1H),5.21(s,2H).
[0113] Example 28: Synthesis of Precursor Compound 28
[0114]
[0115] Intermediate 27 (180 mg, 0.66 mmol) was dissolved in 10 mL of dichloromethane, p-toluenesulfonic anhydride (430.8 mg, 1.32 mmol) was added, and after stirring for 30 minutes, 1M trimethylamine tetrahydrofuran solution (13.2 mL, 13.2 mmol) was slowly added. After stirring for 30 minutes, p-toluenesulfonic anhydride (215.4 mg, 0.66 mmol) was added, and stirred for 30 minutes. P-toluenesulfonic anhydride (215.4 mg, 0.66 mmol) was added twice. After reacting at room temperature for 10 hours, the organic phase was washed with water, the aqueous phase was combined and concentrated under reduced pressure, and the obtained solid was dissolved in dichloromethane and added dropwise to rapidly stirred ether. A precipitate was precipitated, centrifuged, and the supernatant was discarded. Ether was added three times to wash the solid, the supernatant was discarded after centrifugation, and a white solid was obtained after vacuum drying. Further purification was carried out by preparative HPLC with a C18 reverse phase column and a mobile phase of 20% acetonitrile in water (containing 0.1% TFA) at a flow rate of 4 mL / min. The product retention time was 25.4 minutes. A white solid was obtained after freeze drying with an overall yield of 20.0%. 1 H NMR (400MHz, DMSO-d6) δ8.82–8.75(m,1H),8.34(dd,J=8.6,2.3Hz,1H),8.13(d,J=8.6Hz,1H),8.01(d,J=9.5Hz,1H),7. 68(d,J=8.7Hz,1H),7.15(d,J=2.5Hz,1H),7.07(dd,J=8.6,2.5Hz,1H),6.33(d,J=9.5Hz,1H),5.40(s,2H),3.59(s,9H).
[0116] Example 29: Synthesis of Intermediate Compound 29
[0117]
[0118] According to the preparation method of compound 1, intermediate 29 was prepared from 4-iodobenzyl bromide and 7-hydroxycoumarin as a white solid (470 mg) with a yield of 33.5%. 1 H NMR (400MHz, CDCl3) δ7.73(d,J=8.4Hz,2H),7.63(dd,J=9.5,0.6Hz,1H),7.38(d,J=8.6Hz,1H),7.21 –7.15(m,2H),6.89(dd,J=8.6,2.5Hz,1H),6.86(d,J=2.4Hz,1H),6.26(d,J=9.5Hz,1H),5.07(s,2H).
[0119] Example 30: Synthesis of Precursor Compound 30
[0120]
[0121] Intermediate 29 (113.4 mg, 0.3 mmol) was dispersed in 10 mL of chloroform, and m-chloroperbenzoic acid (m-CPBA) (62.1 mg, 0.36 mmol) was added. After reacting at room temperature for 3 hours, the solvent was removed under reduced pressure, and the obtained solid was dissolved in dichloromethane and washed with 100 mL of saturated sodium chloride solution. The organic phase was dried over magnesium sulfate and concentrated under reduced pressure to obtain a white solid. The solid was dispersed in 15 mL of ethanol, and SPIAd (70.9 mg, 0.3 mmol, dissolved in 10% Na2CO3 solution) was added and reacted at room temperature for 1 hour. After the reaction was completed, 30 mL of water was added to the reaction bottle, extracted with DCM (4×20 mL), the organic phases were combined and dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure to obtain a white solid. The solid was ultrasonically washed with dichloromethane and petroleum ether, transferred into a centrifuge tube for centrifugation, and the supernatant was discarded. The washing was repeated twice, and after drying, 40.5 mg of a white solid was obtained, with a yield of 23.4%. 1 H NMR (400MHz, DMSO-d6) δ7.98(d,J=9.5Hz,1H),7.80(d,J=8.3Hz,2H),7.64(d,J=8.6Hz,1H),7.54(d,J=8.4Hz,2H),7.07(d,J=2.4Hz,1H),7. 02(dd,J=8.6,2.4Hz,1H),6.30(d,J=9.5Hz,1H),5.27(s,2H),2.32(s,2H),1.94(s,2H),1.91(s,2H),1.79(s,2H),1.66(s,4H),1.62(s,2H).
[0122] Example 31: MAO-A / B activity assay
[0123] 1. Experimental steps
[0124] 1. MAO-A Activity Assay
[0125] (1) The MAO suspension extracted from mouse liver homogenate was diluted with PBS, the standard working curve was determined and the appropriate enzyme dosage was selected. In this experiment, the enzyme was diluted 2 times.
[0126] (2) Prepare substrate solution: weigh 7.97 mg of tyramine and dissolve it in 10 mL of PBS solution; prepare colorimetric solution: weigh 2 mg of horseradish peroxidase and add 2 mL of distilled water to obtain horseradish peroxidase solution for later use. Accurately weigh 2.03 mg of 4-aminoantipyrine and 3.36 mg of vanillin, add 19.6 mL of PBS solution to dissolve them, and then add 400 μL of the prepared horseradish peroxidase solution; prepare inhibitor: 1000 nM selegiline aqueous solution.
[0127] (3) Add 30 μL of enzyme solution and 25 μL of inhibitor to a 96-well transparent plate and incubate at 37°C for 30 minutes; then add 50 μL of the sample to be tested with gradient concentrations (10 -4 -10 -10 M) Continue incubation for 30 minutes; add substrate and color developer solution in sequence and continue incubation for 90 minutes.
[0128] (4) After the test, the UV absorbance at 490 nm was measured using an ELISA instrument. The IC was calculated using the final concentration of the sample as the horizontal axis and the absorbance as the vertical axis. 50 value.
[0129] 2. MAO-B Activity Assay
[0130] (1) Prepare the compound to be tested into a series of gradient concentrations (10 -4 -10 -10 M) in PBS containing 10% DMSO.
[0131] (2) Prepare working solutions. First, prepare solution 1: dissolve 0.5 mg Amplex Red in 100 μL DMSO; solution 2: dissolve 2 mg horseradish peroxidase in 1.5 mL PBS solution; solution 3: dissolve 14 mg substrate (benzylamine hydrochloride) in 1 mL water. (Solutions 1-3 should be prepared immediately before use). Then take 100 μL of solution 1, 50 μL of solution 2, and 250 μL of solution 3, and add PBS solution to make the total volume 5 mL.
[0132] (3) Prepare enzyme solution: Take 10 μL of pre-packaged MAO-B (25 mg / mL) and dilute to 10 mL with PBS.
[0133] (4) 20 μL of the test compound solution and 98 μL of the enzyme solution were added to a black 96-well plate in sequence and incubated at 37°C for 30 min. After the incubation, 82 μL of the pre-configured working solution was added. After incubation at 37°C for 10 min, the fluorescence intensity was measured using a microplate reader at an excitation wavelength of 535 nM and an emission wavelength of 587 nM.
[0134] (5) Calculate the IC50 value using the logarithm of the final concentration of the sample to be tested as the horizontal axis and the fluorescence intensity as the vertical axis.
[0135] Table 1 Results of MAO-A / B activity determination of compounds
[0136]
[0137]
[0138] 1 NA means "not applicable"
[0139] Example 32: Aβ activity assay
[0140] 1. Experimental steps
[0141] (1) 100 μL of radioligand ([ 125 I]IMPY, 100000 cpm / 100 μL), 100 μL of ethanol solution of the compound (10 -4 M to 10 -10 M), 700 μL BSA (0.1% PBS solution) and Aβ 1-42 Aggregates (100 μL, final concentration 0.7 μM) were added sequentially into borosilicate glass test tubes.
[0142] (2) Incubate at 37°C for 2 hours.
[0143] (3) The cells were separated by filtration using an MP-48T cell collector and washed three times with 10% ethanol.
[0144] (4) Collect the samples containing Aβ 1-42 Aggregate-bound 125 The glass fiber filter paper containing I ligand was placed at the bottom of the numbered counting tube, and the radioactive count of each counting tube was measured using Wizard2 2480γ counter from PerkinElmer, USA. 50 ) was obtained by fitting calculation, and the inhibition constant (K i ) is calculated according to the Cheng-Prusoff equation: K i =IC 50 / (1+[L] / K d ).
[0145] 2. Experimental Results
[0146] The experimental results are shown in Table 2. Most compounds have an activity against Aβ (K i ) is at the micromolar level, indicating that this series of compounds has a very poor binding ability to Aβ and a low degree of off-target binding.
[0147] Table 2: Compound Aβ 1-42 Activity test results
[0148]
[0149]
[0150] Embodiment 33: 18 Preparation of F-labeled compounds
[0151] 1. Experimental steps
[0152] 1. Compounds 18 F]2,[ 18 Preparation of F]4
[0153] [ 18 F]F - The ions were concentrated on the QMA column and then washed with 1 mL of eluent (ACN / H2O, v / v=4:1; 13 mg K 2,2,2 ,1.1mg K2CO3) will [ 18 F]F - Elute from the QMA column into a 10 mL penicillin vial, heat in a 120 °C metal bath, blow dry with N2 continuously, then add 1 mL of anhydrous acetonitrile for azeotropic evaporation and blow dry, repeat three times to ensure that the reaction system is free of water. Dissolve 1 mg of the labeled precursor compound in 0.5 mL of anhydrous acetonitrile and transfer the solution to a container containing [ 18 F]F - The mixture was purified by a pre-treated Sep-Pak C18 solid phase extraction column, and the column was rinsed with 10 mL of deionized water to remove unreacted [ 18 F]F - The column was washed with 1 mL of anhydrous ethanol to elute the labeled compound and the labeled precursor compound adsorbed on the column, and separated and purified by high performance liquid chromatography equipped with a γ-radiation scintillation detector using a Venusil MP C18 analytical column (5 μm, 10 mm × 250 mm), collecting the effluent of the target product, drying the solvent with nitrogen, dissolving the obtained product in 10% ethanol and preparing it to the required concentration with purified water.
[0154] 2. Compounds 18 Preparation of F]9
[0155] [ 18 F]F - The ions were concentrated on the QMA column and then washed with 1 mL of eluent (ACN / H2O, v / v=4:1; 13 mg K 2,2,2 ,1.1mg K2CO3) will [ 18 F]F - Elute from the QMA column into a 10 mL penicillin vial, heat in a 120 °C metal bath, blow dry with N2 continuously, then add 1 mL of anhydrous acetonitrile for azeotropic evaporation and blow dry, repeat three times to ensure that the reaction system is free of water. Dissolve 3 mg of the labeled precursor compound in 300 μL of anhydrous DMF and transfer the solution to a flask containing [ 18 F]F - in a glass reaction tube. Heat the reaction at 120°C for 10 minutes. Cool and separate and purify the product using a Venusil MPC18 analytical column (5μm, 10mm×250mm) with a γ-radiation scintillation detector. Collect the effluent of the target product. Dilute the effluent with 20mL of water, extract the mixture through a pretreated Sep-Pak C18, wash the Sep-Pak column with 10mL of deionized water, and elute the product with 1mL of anhydrous ethanol. Prepare a 10% ethanol saline solution for subsequent animal experiments.
[0156] 2. Experimental Results
[0157] [ 18 F]2,[ 18 F]4,[ 18 The labeling rate of F]9 is greater than 50%, and after HPLC separation and purification, the radiochemical purity is greater than 95%. The chromatographic column is a Venusil MP C18 reverse column (5μm, 10mm×250mm), and the flow rate of the mobile phase is 4mL / min.
[0158] Example 34: Determination of lipid-water partition coefficient
[0159] 1. Experimental steps:
[0160] 1. Take 3 mL of n-octanol and 3 mL of PBS solution in a 15 mL centrifuge tube, add 100 μCi of purified radioligand with a pipette, vortex for 3 minutes, and centrifuge for 3 minutes. Take 100 μL of sample from n-octanol and PBS solution respectively, measure the radioactivity count and calculate the lipid-water partition coefficient according to the following formula.
[0161]
[0162] 2. Take out 1 mL of n-octanol and put it in another centrifuge tube, add 2 mL of n-octanol and 3 mL of PBS solution, vortex for 3 minutes, and centrifuge for 3 minutes. Take 100 μL of sample from n-octanol and 500 μL of sample from PBS solution, repeat the measurement and calculation until a stable Log D value is obtained.
[0163] 2. Experimental Results
[0164] The Log D of compounds 2, 4 and 9 were measured to be 2.17, 2.33 and 2.66, respectively.
[0165] Example 35: In vivo autoradiography inhibition experiment and immunohistochemical staining
[0166] 1. Experimental steps:
[0167] (1) In vivo autoradiography inhibition experiment
[0168] 30 minutes before the injection of radioactive tracer, the inhibitor selegiline saline solution was injected into the tail vein of the rats in the inhibition group (the dosage was calculated as 1 mg / kg), and the control group was not treated. 18 F]2 or [ 18 F]9 (79.6-157.0MBq, 0.1mL, physiological saline solution containing about 10% ethanol), dissect it and take out the whole brain after 15 minutes. Apply OCT embedding agent evenly on the base of the sample holder, fix the whole rat brain according to the horizontal section position and put it into a freezing microtome with an overall ambient temperature of -20°C for freezing. After the sample is completely frozen, fix the sample holder as a whole on the cutting table, adjust the angle between the slice and the sample, and adjust the thickness of the brain slice to 25μm. After the slide containing the brain slice is dried, place it under a phosphor screen for exposure for 2 hours. After the exposure is completed, place the phosphor screen in an autoradiography imaging system in a dark room for scanning.
[0169] (2) Immunohistochemical staining
[0170] The frozen sections of rat brain of the same section were soaked in pre-cooled PBS solution for 5 minutes, and then soaked in pre-cooled acetone for 30 minutes to fix the cell morphology. Then, they were soaked in pre-cooled TE solution (pH=9) containing 0.3% TritonX-100 for 20 minutes, and 3% H2O2 methanol solution for 10 minutes to block endogenous catalase. After rinsing, they were incubated in 3% BSA solution at room temperature for 1 hour to block serum. After rinsing, the primary antibody (monoamine oxidase, proteintech, 12602-1-AP, dilution ratio 1:100) was added and incubated at 4°C overnight. After rewarming, they were rinsed with TBST, and then the secondary antibody (Goat anti-rabbit (HRP*) (RS0002), dilution ratio 1:1000) was added and incubated for 1-2 hours. After the end, the sections were sealed and scanned.
[0171] 2. Experimental results:
[0172] The experimental results are as follows Figure 2 As shown, the in vivo autoradiography results showed that the tracer [ 18 The radioactive signal intensity of the rats in the inhibition group injected with selegiline in advance at the same position in the above-mentioned areas was significantly reduced. 18 F]9 has a higher affinity for MAO-B and a wider area of specific uptake in the rat brain. In addition to the striatum, ependyma of the lateral ventricles and habenula, radioactive signal accumulation was also observed in the hippocampus, cerebellum and cerebral cortex. The radioactive signal of the tracer in the above areas can be effectively inhibited by selegiline. The experimental results verified that the tracer [ 18 F]2 and [ 18 F]9 can specifically bind to MAO-B.
[0173] The results of immunofluorescence staining were consistent with those of autoradiography. Fluorescent signals of astrocyte morphology could be observed in areas where radioactive signals were concentrated (ependyma of the lateral ventricles, habenular nuclei, striatum, cerebellum, etc.), further confirming that the tracer accumulated in areas with high expression of MAO-B in the brain and specifically bound to the target.
[0174] Example 36: Biodistribution experiment in normal mice
[0175] 1. Experimental steps:
[0176] 5-10 μCi 18F-labeled compound (100 μL physiological saline solution, containing 10% ethanol) was injected into normal mice (ICR, male, 3-4 weeks old) via tail vein (n=3), and mice were killed 2 and 60 minutes after injection, respectively. The relevant organs were removed by dissection, and the wet weight and radioactivity count were measured. The data were expressed as the percentage of radioactivity per gram of organ (%ID / g).
[0177] 2. Experimental results:
[0178] The experimental results are shown in Table 3. 18 F]2,[ 18 F]4 and [ 18 F]9 can pass through the blood-brain barrier smoothly, with brain uptake reaching a peak at 2 minutes and clearing quickly in the brain of normal mice. Bone uptake was low within 0-60 minutes, and it was preliminarily judged that the probe had good stability in vivo and no obvious metabolic defluorination phenomenon.
[0179] Table 3: Compounds [ 18 F]2,[ 18 F]4 and [ 18 Results of animal distribution of F]9 in normal mice
[0180]
[0181] Example 37: SD rat micro-PET / CT imaging and inhibition experiment.
[0182] 1. Experimental methods:
[0183] The inhibitory SD rats (n=2, 350-500g) were injected with the inhibitor selegiline solution (2.5mg / mL, the dosage was calculated as 1mg / kg) through the tail vein 30 minutes in advance, while the control rats (n=1-2, 400-485g) were not treated. 18 F]2 or [ 18 F]9 (12.8-14.2MBq, 0.5-0.8mL, 10% ethanol in saline) was injected into rats via the tail vein, followed by a 0-60 minute head PET dynamic scan with frames of 15×1min, 5×5min, and 2×10min; and after the head dynamic scan, a 60-70 minute whole-body PET / CT scan was performed. After data acquisition, quantitative data correction and automatic reconstruction were performed. Using CT as the basis for positioning, the region of interest (ROI) was drawn on the PMOD software, the standardized uptake value (SUV) of the region was calculated, and the time-activity curves (TACs) were constructed.
[0184] 2. Experimental results:
[0185] The results of dynamic micro-PET / CT scanning of SD rats showed that [ 18 F]2 and [ 18 F]9 can quickly pass through the blood-brain barrier (BBB), and the accumulation of radioactive signals in the brain area is clearly visible. 18 F]2 whole brain uptake value SUV 1 minute after injection max =2.18, the radioactive signal in the brain was basically completely cleared in 60 minutes, SUV 1min / 60min =12.0;[ 18 F]9 uptake in the whole brain reached its peak 2 minutes after injection, and SUV max =2.13, then cleared rapidly from the brain, SUV 2min / 60min =7.9. The in vivo micro-PET / CT imaging results were basically consistent with the in vitro biodistribution.
[0186] The results of the inhibition experiment showed that the early injection of the inhibitor selegiline could reduce [ 18 F]2 and [ 18 F]9 uptake in the brain, and [ 18 F]9 showed a more significant inhibition, which also confirmed that [ 18 F]9 has a high affinity for MAO-B.
[0187] Example 38: PET imaging of APP / PS1 model mice
[0188] 1. Experimental methods:
[0189] APP / PS1 model mice (n=3, 22 months old, 30-35 mg) or C57BL / 6 control mice (n=2, 22 months old, 32 mg) were intravenously administered with the labeled compound under isoflurane anesthesia. 18 F]2, the data were collected by the instrument immediately. The collection procedure and data reconstruction processing method were the same as those in Example 37.
[0190] 2. Experimental results:
[0191] The micro-PET / CT imaging results showed that [ 18 F]2 showed good biological properties in APP / PS1 and C57BL / 6 mice, with high initial uptake and fast brain clearance in all brain regions. The initial brain uptake value SUV of APP / PS1 mice was 1min =2.29, clearance rate SUV 1min / 60min =12.3; C57BL / 6 mouse brain uptake value SUV 1min =2.51, clearance rate SUV 1min / 60min=12.1. Compared with the control group C57BL / 6 mice, there was no significant difference in the initial brain volume and clearance rate of APP / PS1 model mice.
Claims
1. An aryl benzyl ether compound, characterized in that: It has the following general formula (I): in: X1 represents N or CH; X2, X3 each independently represent O or CH2; R1, R2, and R3 each independently represent H, 123 / 124 / 125 / 127 I, 18 / 19 F or O(CH2) n 18 / 19 F, n represents 1-6; Ar represents 2. The aryl benzyl ether compound according to claim 1, characterized in that Selected from the following compounds: Among them, F in compound 1-19 is 18 F or 19 F.
3. The derivative of the aryl benzyl ether compound according to claim 1 or 2, characterized in that: The invention also comprises pharmaceutically acceptable salts, esters or amides of the aryl benzyl ether compounds.
4. The derivative according to claim 3, characterized in that The pharmaceutically acceptable salts of the aryl benzyl ether compounds include hydrochlorides, phosphates and sulfonates of the aryl benzyl ether compounds.
5. A monoamine oxidase B inhibitor, characterized in that The active ingredient is the aryl benzyl ether compound as claimed in claim 1 or 2, or the derivative of the aryl benzyl ether compound as claimed in claim 3 or 4.
6. A diagnostic or detection reagent for a central nervous system disease characterized by upregulated expression of monoamine oxidase B, characterized in that: The active ingredient is the aryl benzyl ether compound as claimed in claim 1 or 2, or the derivative of the aryl benzyl ether compound as claimed in claim 3 or 4.
7. The diagnostic or detection reagent according to claim 6, characterized in that The diseases include Alzheimer's disease, Parkinson's disease, frontotemporal lobar degeneration, chronic traumatic encephalopathy, progressive supranuclear palsy, primary age-related tauopathy, Pick's disease, corticobasal degeneration, glial cell globular inclusion tauopathy, amyotrophic lateral sclerosis and Lewy body dementia, etc.
8. Use of the aryl benzyl ether compound according to claim 1 or 2, or the derivative according to claim 3 or 4 in the preparation of a nuclear medicine imaging agent.
Citation Information
Patent Citations
Coumarin derivative with anti-breast cancer activity and application thereof
CN118852077A
